#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

De-intensification of treatment in patient with diabetes mellitus could be beneficial

Czech version

Authors: Peter Jackuliak
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in: Forum Diab 2021; 10(1): 29-33
Category:

Overview

The fixed combination of basal insulin and GLP-1 receptor agonist can be considered as effective and safe choice for intensifying of treatment. As well it can be justifiable for de-intensification in patient treated with multiple daily insulin injections, including in patients with not bad glucose control and with high insulin doses. The article provides an overview of the knowledge on the mechanism for de-intensifying the treatment using fixed combination of antidiabetic drugs.

Keywords:

basal insulin – de-intesification of treatment – GLP1 RA

Sources
  2. Wangnoo SK, Sethi B, Sahay RK et al. Treat-to-target trials in diabetes. Indian J Endocrinol Metab 2014; 18(2): 166–174. Dostupné z DOI: <http://dx.doi.org/10.4103/2230–8210.129106>.
  3. White RD. The treat-to-target A1C approach to control type 2 diabetes and prevent complications. Adv Ther 2007; 24(3): 545–559. Dostupné z DOI: <http://dx.doi.org/10.1007/BF02848777>.
  4. Garber A. Treat-to-Target Trials: Uses, Interpretation, and Review of Concepts. Diabetes Obes Metab 2014; 16(3): 193–205. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12129>.
  5. Masterton RG. Antibiotic de-escalation. Crit Care Clin 2011; 27(1): 149–162. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ccc.2010.09.009>.
  6. Jermendy G. [De-escalation of antihyperglycemic treatment in patients with type 2 diabetes – when less is more]. Orv Hetil 2019; 160(31): 1207–1215. Dostupné z DOI: <http://dx.doi.org/10.1556/650.2019.31488>.
  7. McAlister FA, Youngson E, Eurich DT. Treatment Deintensification Is Uncommon in Adults With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes 2017; 10(4): e003514. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCOUTCOMES.116.003514>.
  8. Hart HE, Rutten GE, Bontje KN et al. Overtreatment of older patients with type 2 diabetes mellitus in primary care. Diabetes Obes Metab 2018; 20(4): 1066–1069. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13174>.
  9. [American Diabetes Association]. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2021. Diabetes Care 2021; 44(Suppl 1): S111-S124. Dostupné z DOI: <http://dx.doi.org/10.2337/dc21-S009>.
  10. Maiorino MI, Chiodini P, Bellastella G et al. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2017; 40(4): 614–624. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–1957>.
  11. Eng C, Kramer CK, Zinman B et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014; 384(9961): 2228–2234. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(14)61335–0>.
  12. Aroda VR, González-Galvez G, Randi Grøn R et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7(8): 596–605. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(19)30184–6>.
  13. Niswender KD. Basal insulin: physiology, pharmacology, and clinical implications. Postgrad Med 2011; 123(4): 17–26. Dostupné z DOI: <http://dx.doi.org/10.3810/pgm.2011.07.2300>.
  14. Hinnen D, Kruger DF. Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. Diabetes Metab Syndr Obes 2019; 12: 447–455. Dostupné z DOI: <http://dx.doi.org/10.2147/DMSO.S188705>.
  15. Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr 2017; 30(3): 202–210. Dostupné z DOI: <http://dx.doi.org/10.2337/ds16–0026>.
  16. Baggio LL, DruckerDJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132(6): 2131–2157. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2007.03.054>.
  17. Moreira RO, Cobas R, Lopes Assis Coelho RC. Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? Diabetol Metab Syndr 2018; 10: 26. Dostupné z DOI: <http://dx.doi.org/10.1186/s13098–018–0327–4>.
  18. Gough SC, Bode BW, Woo VC et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab 2015; 17(10): 965–973. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12498>.
  19. Uccellatore A, Genovese S, Dicembrini I et al. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Ther 2015; 6(3): 239–256. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–015–0127-x>.
  20. Linjawi S, Bode BW, Chaykin LB et al. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther 2017; 8(1): 101–114. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–016–0218–3>.
  21. Kapitza C, Bode B, Ingwersen HS et al. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol 2015; 55(12): 1369–1377. Dostupné z DOI: <http://dx.doi.org/10.1002/jcph.549>.
  22. Rodbard HW, Bode BW, Harris SB et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabet Med 2017; 34(2): 189–196. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.13256>.
  23. Harris SB, Kocsis G, Prager R et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab 2017; 19(6): 858–865. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12892>.
  24. Price H, Blüher M, Prager R et al. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab 2018; 20(4): 954–962. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13182>.
  25. Sofra D. Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center. Diabetes Ther 2017; 8(2): 377–384. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–017–0234-y>.
  26. Billings LK, Doshi A, Didier Gouet D et al. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabetes Care 2018; 41(5): 1009–1016. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–1114>
  27. Watada H, Ross Agner BF, Doshi A et al. IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy. Diabetes Ther 2020; 11(1): 331–339. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–019–00730-y>.
  28. Watada H, Kaneko S, Komatsu M et al. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial. Diabetes, Obes Metab 2019; 21(12): 2694–2703. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13859>.
  29. Taybani Z, Bótyik B, Katkó M et al. Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes. Diabetes Ther 2019; 10(5): 1869–1878. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–019–0673–8>.
  30. Boye KS, Curtis SE, Lage MJ et al. Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherence 2016; 10: 1573–1581. Dostupné z DOI: <http://dx.doi.org/10.2147/PPA.S107543>.
  31. Roussel R, Charbonnel B, Behar M et al. Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. Diabetes Ther 2016; 7(3): 537–549. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–016–0185–8>.
  32. Miller E, Doshi A, Grøn R et al. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy. Diabetes Obes Metab 2019; 21(12): 2643–2650. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13851>.
  33. Wysham CH, Campos C, Kruger D. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications. Clin Diabetes 2018; 36(2): 149–159. Dostupné z DOI: <http://dx.doi.org/10.2337/cd17–0064>.
Labels
Diabetology Endocrinology Internal medicine
Osteoporosis in endocrinopathies
Assessment of the osteoporosis risk in patients with type 2 diabetes mellitus – when bone mineral density measurement is not sufficient
Osteoporosis management in diabetic patient
Contribution of metformin therapy with extended release formulas
Population differences in the prevalence of diabetes mellitus, its risk factors and complications
Second generation basal insulin analogues in clinical trials using continuous monitoring of glucose levels
Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports
Diabetic macular oedema treatment with intravitreal dexamethasone: case report
Article was published in

Forum Diabetologicum

Issue 1
2021 Issue 1
Download issue PDF
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#